Zirabev 400 Vial — Bevacizumab 400 mg/16 ml (1 Vial) Pfizer
Zirabev 400 mg/16 ml (Bevacizumab) is a highly effective targeted cancer therapy. It is a recombinant humanized monoclonal antibody that binds to the vascular endothelial growth factor (VEGF). By blocking VEGF, Zirabev prevents the formation of new blood vessels that tumors need to grow. Deprived of oxygen and essential nutrients, the tumor is starved and its progression is halted.
Manufacturer: Pfizer (USA). 🇹🇷 Note: This specific product holds official Turkish registration. It is a premium biosimilar to the well-known brand Avastin, manufactured by the global pharmaceutical giant Pfizer for the domestic market of Turkey, ensuring strict adherence to international quality standards.
Key Features:
- ✅ Anti-Angiogenic Effect: Directly targets and cuts off the tumor's blood supply.
- ✅ Broad Applicability: Proven effective in treating a wide variety of solid tumors.
- ❄️ COLD CHAIN REQUIRED: This medication must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze!
Prescribed by an oncologist, either as a monotherapy or in combination with chemotherapy, for the treatment of:
- 🔹 Metastatic colorectal cancer.
- 🔹 Advanced, metastatic, or recurrent non-squamous non-small cell lung cancer (NSCLC).
- 🔹 Advanced and/or metastatic renal cell carcinoma (kidney cancer).
- 🔹 Glioblastoma (a recurrent malignant brain tumor).
- 🔹 Epithelial ovarian, fallopian tube, or primary peritoneal cancer, and cervical cancer.
Sales Unit: Carton containing 1 glass vial of concentrate for solution for infusion (400 mg / 16 ml).
⚠️ APPLICATION INSTRUCTIONS:
- Intravenous Infusion ONLY: The drug must be administered only as an intravenous (IV) drip by a qualified healthcare professional in a clinical setting. It must NEVER be administered as an IV push or bolus!
- Dosage: Calculated individually by the doctor based on the patient's body weight and the specific treatment protocol (typically 5 mg, 7.5 mg, 10 mg, or 15 mg per kg of body weight, given every 2 or 3 weeks).
- Preparation: The vial must be diluted with normal saline (0.9% sodium chloride) prior to administration.
- ⛔ Recent Surgery: Strictly contraindicated for at least 28 days following major surgery or until the surgical wound has fully healed (the drug impairs tissue healing).
- ⛔ Bleeding: Patients with a history of severe hemorrhage or recent coughing up of blood (hemoptysis).
- Pregnancy and breastfeeding (causes severe fetal harm).
- Hypersensitivity to bevacizumab or any other recombinant human or humanized antibodies.
Therapy must be conducted under the strict supervision of an oncologist. Potential side effects include:
- 🫀 Cardiovascular: High blood pressure (hypertension) is very common and requires monitoring and possible blood pressure medication. Increased risk of blood clots (thromboembolism).
- 🩸 Bleeding: Increased risk of hemorrhage (ranging from nosebleeds to severe internal bleeding).
- ⚠️ Gastrointestinal: Risk of gastrointestinal perforation (a rare but severe complication).
- 🟡 Kidneys: Excess protein in the urine (proteinuria).
- 💤 General: Impaired wound healing, asthenia (severe weakness), fatigue.
Similar products
What Customers Say
No reviews yet
Your review can be the first!